Menu Back toSession-0702-Safety-Evaluation-of-New-Types-of-Antibodies

The 7th DIA China Annual Meeting


Session 0702 Safety Evaluation of New Types of Antibodies

Session Chair(s)

Jufeng  Wang

Jufeng Wang

  • Director
  • National Institutes for Food and Drug Control, China

Current Challenges and Opportunities in Preclinical Safety Assessment of Multi-specific Biologics

Speaker(s)

Hong  Wang

Current Challenges and Opportunities in Preclinical Safety Assessment of Multi-specific Biologics

Hong Wang

  • Senior Scientist/Oncology Therapeutic Area Leader
  • Genentech, a Member of Roche Group, China
Yan  Huo

Yan Huo

  • Director of General Toxicology, NCSED
  • CFDA, China
James  Yan

Preclinical Development for Monoclonal Antibody (mAb) Current Practice and Future Direction

James Yan

  • Executive Director & Site Lead
  • Covance, China

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU: jxu@kellencompany.com, or Sofie Peeters: speeters@kellencompany.com
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
dia@diachina.org
Tel: +86 10 5704 2650